ClinConnect ClinConnect Logo
Search / Trial NCT06190002

Characteristics and Risk Factors for Invasive Fungal Infection With Acute-on-chronic Hepatitis B Liver Failure

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Jan 2, 2024

Trial Information

Current as of July 12, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the risk factors and characteristics of invasive fungal infections in patients who have acute-on-chronic hepatitis B liver failure. This condition occurs when chronic hepatitis B, a long-term liver infection, worsens suddenly, leading to serious liver function problems. The researchers are looking at patients admitted to Qilu Hospital of Shandong University between January 2010 and July 2023 to understand how these infections develop and what makes some patients more vulnerable.

To be eligible for this study, participants must be adults (18 years and older) diagnosed with acute liver injury related to chronic hepatitis B, showing specific signs such as high bilirubin levels or issues with blood clotting. They should also have experienced complications like fluid buildup in the abdomen or confusion due to liver failure within the last month. However, those who have other severe conditions, like liver cancer or certain autoimmune diseases, or who unfortunately passed away shortly after admission, will not be included. Since this trial is not yet recruiting participants, there's no immediate action required, but it aims to gather valuable insights that may help improve treatment and outcomes for future patients with this serious liver condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Acute liver function injury TBIL≥5mg/dl(85umol/L) and international normalized ratio (INR) ≥1.5 or PTA≤40% based on previously known chronic hepatitis B or compensated cirrhosis.
  • Combined with ascites and/or hepatic encephalopathy within 4 weeks.
  • HBsAg(+)\>6 months
  • Exclusion Criteria:
  • Patients died within 48 hours of admission or withdrew treatment.
  • Combined with liver cancer and other extrahepatic organ malignant tumors, rheumatic diseases, hyperthyroidism.
  • Age \<18 years old.

About Qilu Hospital Of Shandong University

Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.

Locations

Patients applied

0 patients applied

Trial Officials

Yu-Chen Fan, MD,PhD

Study Chair

Qilu Hospital of Shandong University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported